These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25345953)

  • 1. [Therapeutic effect of vildagliptin and insulin aspart injection in elderly patients with type 2 diabetes].
    Xu L; Lin K; Deng H; Li Y; Zhi X; Zhang W; Wu W
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Oct; 34(10):1511-8. PubMed ID: 25345953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
    Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
    Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
    Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
    Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
    Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
    J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
    Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
    J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial.
    Haidinger M; Werzowa J; Hecking M; Antlanger M; Stemer G; Pleiner J; Kopecky C; Kovarik JJ; Döller D; Pacini G; Säemann MD
    Am J Transplant; 2014 Jan; 14(1):115-23. PubMed ID: 24279801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
    Rosenstock J; Fitchet M
    Int J Clin Pract Suppl; 2008 Mar; (159):15-23. PubMed ID: 18269437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
    Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
    Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
    Hassanein M; Abdallah K; Schweizer A
    Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    He YL; Foteinos G; Neelakantham S; Mattapalli D; Kulmatycki K; Forst T; Taylor A
    Diabetes Obes Metab; 2013 Dec; 15(12):1111-9. PubMed ID: 23782529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
    Schweizer A; Dejager S; Bosi E
    Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
    Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety of vildagliptin as a second-line therapy vs other oral antidiabetic agents in patients with type 2 diabetes: Czech results within the worldwide prospective cohort EDGE study].
    Haluzík M; Veselá V; Gerle J; Brada M; Dohnalová L; Edelsberger T; Houdová J
    Vnitr Lek; 2013 Dec; 59(12):1049-56. PubMed ID: 24350936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
    Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.
    Foley JE; Bunck MC; Möller-Goede DL; Poelma M; Nijpels G; Eekhoff EM; Schweizer A; Heine RJ; Diamant M
    Diabetologia; 2011 Aug; 54(8):1985-91. PubMed ID: 21547496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Difference between observed and predicted glycated hemoglobin at baseline and treatment response to vildagliptin-based dual oral therapy in patients with type 2 diabetes.
    Wang JS; Hung YJ; Lu YC; Tsai CL; Yang WS; Lee TI; Hsiao YC; Sheu WH
    Diabetes Res Clin Pract; 2018 Apr; 138():119-127. PubMed ID: 29444447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.